Premium
Overview of drug data within French health insurance databases and implications for pharmacoepidemiological studies
Author(s) -
Palmaro Aurore,
Moulis Guillaume,
Despas Fabien,
Dupouy Julie,
LapeyreMestre Maryse
Publication year - 2016
Publication title -
fundamental and clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.655
H-Index - 73
eISSN - 1472-8206
pISSN - 0767-3981
DOI - 10.1111/fcp.12214
Subject(s) - pharmacoepidemiology , medicine , prescription drug , checklist , medical prescription , database , identification (biology) , reimbursement , drug , identifier , sample (material) , health care , formulary , data science , family medicine , pharmacology , computer science , political science , psychology , chemistry , botany , chromatography , law , cognitive psychology , biology , programming language
In this study, we aimed to provide an updated overview of drug data contained in the French health insurance database ( SNIIRAM ) and its associated national representative sample ( EGB ). This study identified most common problems concerning drug data: (i) change in level of coverage of drugs of interest (drug no more eligible for reimbursement or no more prescription‐only), (ii) break in patients' eligibility (in connection with change of healthcare plan or patients' identifier), and (iii) technical and regulatory issues. We provide a brief checklist to enable a structured identification of these issues. The impact of gap in drug data availability on study validity will depend on the research question, drug, setting, and population of interest. The French health insurance database and associated sample are valuable resources for pharmacoepidemiological research. There is a need to pursue further methodological and validation studies to promote accurate and transparent use of French health insurance databases for pharmacoepidemiology.